My watch list  

AlloCyte Pharmaceuticals AG (AlloCyte) is a privately held Swiss company founded in November 2011. AlloCyte develops innovative small molecule drugs for severe immune-mediated diseases. AlloCyte targets one of the most powerful families of drug targets, integrins, via a novel pharmacological mechanism. AlloCyte’s activities are financed by private investors and public funds including the Swiss Commission for Technology and Innovation (CTI).


Gabriele Weitz Schmidt
Chief Scientific Officer

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE